Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype

Authors:

Abstract
DNA-hypomethylating agents (HMAs) induce notable remission rates in AML/MDS patients withTP53mutations; however, secondary resistance often develops rapidly. In the DECIDER trial (NCT00867672), elderly AML patients (also those with adverse genetics) randomized to all-transretinoic acid (ATRA) added to decitabine (DEC) attained significantly delayed time-to-resistance. An 82-year-old patient with a non-disruptive, in-frameTP53mutation (p.Cys238_Asn239delinsTyr, VAF 90%) and complex-monosomal karyotype attained a complete hematologic and cytogenetic remission with DEC + ATRA, with 3.7 years survival after 30 treatment cycles that were well-tolerated. Further HMA + ATRA studies appear warranted in AML/MDS patients of different genetic risk groups ineligible for more intensive treatment.Trial registration: This trial was registered at ClinicalTrials.gov identifier: NCT00867672
Funding Information
  • Deutsche Forschungsgemeinschaft (FOR2674 A02, FOR2674 A09, FOR2674 A05)
  • German Federal Ministry of Education and Research (01KG0913)
  • Universitätsklinikum Freiburg

This publication has 15 references indexed in Scilit: